160 related articles for article (PubMed ID: 23339052)
1. Synthesis of long-circulating, backbone degradable HPMA copolymer-doxorubicin conjugates and evaluation of molecular-weight-dependent antitumor efficacy.
Pan H; Sima M; Yang J; Kopeček J
Macromol Biosci; 2013 Feb; 13(2):155-60. PubMed ID: 23339052
[TBL] [Abstract][Full Text] [Related]
2. Backbone degradable multiblock N-(2-hydroxypropyl)methacrylamide copolymer conjugates via reversible addition-fragmentation chain transfer polymerization and thiol-ene coupling reaction.
Pan H; Yang J; Kopecková P; Kopecek J
Biomacromolecules; 2011 Jan; 12(1):247-52. PubMed ID: 21158387
[TBL] [Abstract][Full Text] [Related]
3. HPMA copolymer-doxorubicin-gadolinium conjugates: synthesis, characterization, and in vitro evaluation.
Zarabi B; Nan A; Zhuo J; Gullapalli R; Ghandehari H
Macromol Biosci; 2008 Aug; 8(8):741-8. PubMed ID: 18484565
[TBL] [Abstract][Full Text] [Related]
4. Pronounced Cellular Uptake of Pirarubicin versus That of Other Anthracyclines: Comparison of HPMA Copolymer Conjugates of Pirarubicin and Doxorubicin.
Nakamura H; Koziolová E; Chytil P; Tsukigawa K; Fang J; Haratake M; Ulbrich K; Etrych T; Maeda H
Mol Pharm; 2016 Dec; 13(12):4106-4115. PubMed ID: 27934482
[TBL] [Abstract][Full Text] [Related]
5. Preclinical evaluation of linear HPMA-doxorubicin conjugates with pH-sensitive drug release: efficacy, safety, and immunomodulating activity in murine model.
Sirova M; Mrkvan T; Etrych T; Chytil P; Rossmann P; Ibrahimova M; Kovar L; Ulbrich K; Rihova B
Pharm Res; 2010 Jan; 27(1):200-8. PubMed ID: 19894105
[TBL] [Abstract][Full Text] [Related]
6. Backbone Degradable N-(2-Hydroxypropyl)methacrylamide Copolymer Conjugates with Gemcitabine and Paclitaxel: Impact of Molecular Weight on Activity toward Human Ovarian Carcinoma Xenografts.
Yang J; Zhang R; Pan H; Li Y; Fang Y; Zhang L; Kopeček J
Mol Pharm; 2017 May; 14(5):1384-1394. PubMed ID: 28094954
[TBL] [Abstract][Full Text] [Related]
7. New HPMA copolymer-based drug carriers with covalently bound hydrophobic substituents for solid tumour targeting.
Chytil P; Etrych T; Konák C; Sírová M; Mrkvan T; Boucek J; Ríhová B; Ulbrich K
J Control Release; 2008 Apr; 127(2):121-30. PubMed ID: 18304673
[TBL] [Abstract][Full Text] [Related]
8. Polymer conjugates of doxorubicin bound through an amide and hydrazone bond: Impact of the carrier structure onto synergistic action in the treatment of solid tumours.
Etrych T; Subr V; Laga R; Ríhová B; Ulbrich K
Eur J Pharm Sci; 2014 Jul; 58():1-12. PubMed ID: 24632485
[TBL] [Abstract][Full Text] [Related]
9. Design of a multivalent galactoside ligand for selective targeting of HPMA copolymer-doxorubicin conjugates to human colon cancer cells.
David A; Kopecková P; Minko T; Rubinstein A; Kopecek J
Eur J Cancer; 2004 Jan; 40(1):148-57. PubMed ID: 14687799
[TBL] [Abstract][Full Text] [Related]
10. Synthesis and evaluation of a backbone biodegradable multiblock HPMA copolymer nanocarrier for the systemic delivery of paclitaxel.
Zhang R; Luo K; Yang J; Sima M; Sun Y; Janát-Amsbury MM; Kopeček J
J Control Release; 2013 Feb; 166(1):66-74. PubMed ID: 23262201
[TBL] [Abstract][Full Text] [Related]
11. Star-shaped immunoglobulin-containing HPMA-based conjugates with doxorubicin for cancer therapy.
Etrych T; Mrkvan T; Ríhová B; Ulbrich K
J Control Release; 2007 Sep; 122(1):31-8. PubMed ID: 17631976
[TBL] [Abstract][Full Text] [Related]
12. Polymer conjugates of the highly potent cytostatic drug 2-pyrrolinodoxorubicin.
Studenovsky M; Ulbrich K; Ibrahimova M; Rihova B
Eur J Pharm Sci; 2011 Jan; 42(1-2):156-63. PubMed ID: 21075206
[TBL] [Abstract][Full Text] [Related]
13. Biodegradable multiblock poly(N-2-hydroxypropyl)methacrylamide gemcitabine and paclitaxel conjugates for ovarian cancer cell combination treatment.
Larson N; Yang J; Ray A; Cheney DL; Ghandehari H; Kopeček J
Int J Pharm; 2013 Sep; 454(1):435-43. PubMed ID: 23827653
[TBL] [Abstract][Full Text] [Related]
14. FRET-trackable biodegradable HPMA copolymer-epirubicin conjugates for ovarian carcinoma therapy.
Yang J; Zhang R; Radford DC; Kopeček J
J Control Release; 2015 Nov; 218():36-44. PubMed ID: 26410808
[TBL] [Abstract][Full Text] [Related]
15. Targetable HPMA copolymer-adriamycin conjugates. Recognition, internalization, and subcellular fate.
Omelyanenko V; Kopecková P; Gentry C; Kopecek J
J Control Release; 1998 Apr; 53(1-3):25-37. PubMed ID: 9741911
[TBL] [Abstract][Full Text] [Related]
16. The Potential of Poly[N-(2-hydroxypropyl)methacrylamide] via Reversible Addition-Fragmentation Chain Transfer Polymerization as Safe Nanocarrier.
Zhang Y; Guo C; Li S; Luo K; Hu J; Gu Z
J Nanosci Nanotechnol; 2016 Jun; 16(6):5746-54. PubMed ID: 27427626
[TBL] [Abstract][Full Text] [Related]
17. Conjugates of doxorubicin with graft HPMA copolymers for passive tumor targeting.
Etrych T; Chytil P; Mrkvan T; Sírová M; Ríhová B; Ulbrich K
J Control Release; 2008 Dec; 132(3):184-92. PubMed ID: 18534705
[TBL] [Abstract][Full Text] [Related]
18. Biodistribution and antitumour efficacy of long-circulating N-(2-hydroxypropyl)methacrylamide copolymer-doxorubicin conjugates in nude mice.
Shiah JG; Dvorák M; Kopecková P; Sun Y; Peterson CM; Kopecek J
Eur J Cancer; 2001 Jan; 37(1):131-9. PubMed ID: 11165140
[TBL] [Abstract][Full Text] [Related]
19. Binding and cytotoxicity of HPMA copolymer conjugates to lymphocytes mediated by receptor-binding epitopes.
Tang A; Kopeiková P; Kopeckevá J
Pharm Res; 2003 Mar; 20(3):360-7. PubMed ID: 12669954
[TBL] [Abstract][Full Text] [Related]
20. The structure-dependent toxicity, pharmacokinetics and anti-tumour activity of HPMA copolymer conjugates in the treatment of solid tumours and leukaemia.
Tomalova B; Sirova M; Rossmann P; Pola R; Strohalm J; Chytil P; Cerny V; Tomala J; Kabesova M; Rihova B; Ulbrich K; Etrych T; Kovar M
J Control Release; 2016 Feb; 223():1-10. PubMed ID: 26708020
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
